, nine nonrepetitive isolates of Klebsiella pneumoniae with reduced susceptibility or resistance to carbapenems were recovered from clinical specimens from separate patients hospitalized in a tertiary care hospital. The imipenem-EDTA synergy test was positive for all isolates. PCR, sequencing, and transferability experiments revealed the novel bla VIM-12 metallo-␤-lactamase gene, which was plasmid mediated and located in a class 1 integron. Pulsed-field gel electrophoresis demonstrated a single macrorestriction pattern, indicating the clonal spread of VIM-12-producing K. pneumoniae.
Acquired metallo-␤-lactamases (MBLs) constitute a growing class of ␤-lactamases that readily hydrolyze most ␤-lactam antibiotics, including imipenem and meropenem (20) . They are usually embedded in class 1 integron structures carrying various gene cassettes and belong to the group B ␤-lactamases according to the classification scheme proposed by Ambler (1) . Five different groups of acquired MBLs have been described (IMP, VIM, SPM, GIM, and SIM enzymes), but the first two of these groups have predominated in gram-negative organisms (8, 9, 13, 20) . VIM-type MBLs are commonly encountered among nonfermenters in the Far East and southern Europe (14, 15, 18, 21, 22) , but during the last few years, the respective bla genes have also spread in members of the family Enterobacteriaceae (11, 20, 23) . Reports of VIM-type MBL-producing K. pneumoniae isolates from Greek hospitals are increasing (5, 7) . Recently, a novel VIM-type MBL variant, VIM-12, was identified from a clinical isolate of Klebsiella pneumoniae in Greece (16) . In this report, we describe an outbreak caused by K. pneumoniae harboring the bla VIM-12 gene.
MATERIALS AND METHODS
From November 2006 to April 2007, nine nonrepetitive K. pneumoniae isolates exhibiting reduced susceptibility or resistance to imipenem were isolated from clinical specimens collected from separate patients hospitalized in different medical and surgical wards at Hippokration General Hospital, Thessaloniki, Greece. All patients had a long-term hospitalization and had been treated with multiple courses of antimicrobials, including carbapenems. Identification of the isolates to the species level and initial antibiotic susceptibility testing were performed by the Vitek-2 automated system (BioMérieux, Marcy l'Étoile, France), by which they were characterized as imipenem intermediate or resistant.
Susceptibilities to a range of antimicrobials (amikacin, amoxicillin-clavulanate, ampicillin, aztreonam, cefepime, cefotaxime, cefoxitin, ceftazidime, ciprofloxacin, cotrimoxazole, ertapenem, imipenem, meropenem, and tetracycline) were also determined by disk diffusion (3). MICs of imipenem, meropenem, ertapenem, and tigecycline were additionally determined by Etest (AB Biodisk, Solna, Sweden) and the broth microdilution method (3). Susceptibilities were interpreted according to CLSI guidelines (3), when available. For tigecycline, the U.S.
FDA (Food and Drug Administration) recommendation was used (susceptible, Յ2 g/ml; resistant, Ն8 g/ml). Possible MBL production was tested by using the imipenem-EDTA double-disk synergy test (2, 14) . Escherichia coli strains ATCC 25922 and 35218 and known VIM-12-producing E. coli strain 28 (6) were used as controls in all susceptibility assays.
The isolates were tested by PCR for the bla VIM gene with a set of primers that amplify an internal fragment of the gene (18) . For sequencing, primers amplifying the entire bla VIM gene were also used (21) . Additionally, PCRs were performed with all of the isolates for the bla IMP MBL gene (18) , as well as for the extended-spectrum ␤-lactamase-encoding genes bla TEM , bla CTX-M , and bla SHV-5-type and the AmpC type-encoding gene bla CMY (12, 19) . Detection and mapping of a class 1 integron were carried out with primers specific for 5Ј and 3Ј conserved segments amplifying the variable region containing the resistance gene cassette (10) . Nucleotide sequencing of both strands of the PCR products derived with primers amplifying the whole bla VIM gene and the class 1 integron was performed with an ABI Prism 377 DNA sequencer (Applied Biosystems Division, Perkin-Elmer, Foster City, CA).
The K. pneumoniae clinical isolates studied were subjected to conjugation experiments with E. coli 26R793 (lac Rif r ) as the recipient (17) . Selection of transconjugants was done on MacConkey agar plates containing rifampin at 100 g/ml and ceftazidime at 2 g/ml. Transconjugants were analyzed for plasmids by an alkaline lysis procedure. The plasmid DNA band was extracted from the agarose gel with the QIAquick gel extraction kit (Qiagen GmbH, Hilden, Germany) and was used as template DNA in a PCR for the detection of bla VIM . The expression of the bla VIM gene was tested by reverse transcriptase PCR-specific amplification with DNase-treated RNA extracts obtained with an RNeasy mini kit (Qiagen) and 16S rRNA as a control as described previously (7), with the same RNA extracts for amplification of both the 16S rRNA and bla VIM genes.
The relatedness of the K. pneumoniae isolates was analyzed by pulsed-field gel electrophoresis (PFGE) with XbaI-digested genomic DNA and a CHEF-DRIII system (Bio-Rad, Hemel Hempstead, United Kingdom) as described elsewhere (18) . XbaI macrorestriction patterns were compared visually.
RESULTS
The nine K. pneumoniae isolates studied were recovered from blood cultures, wounds, and bronchial secretions (two cases each) and from urine, sputum, and drainage fluid (one case each). The ages of the patients ranged from 23 to 90 years; they were admitted for several reasons and were hospitalized in six different wards of the hospital. Four of them had received carbapenems prior to the isolation of the bla VIM-12 -producing K. pneumoniae. Table 1 summarizes the characteristics of the patients and the origins of the isolates.
By the automated system, all of the isolates were initially characterized as intermediately resistant or resistant to imi-penem and meropenem (Table 2) . By disk diffusion testing, five of the isolates were susceptible to all carbapenems, three were susceptible to imipenem and meropenem but intermediately resistant to ertapenem, and one was resistant to all three carbapenems. In accordance with disk diffusion, the Etest and broth microdilution MICs for all of the isolates but one were in the susceptible range for imipenem and meropenem (1 to 4 g/ml for imipenem and 0.5 to 4 g/ml for meropenem) and ranged from 0.5 to 16 g/ml for ertapenem, while the remaining isolate had MICs of Ͼ32 g/ml for all three carbapenems ( Table 2 ). The isolates were also susceptible to tigecycline, whose MICs ranged from 0.032 to 2 mg/liter. All of the isolates exhibited synergy with EDTA in the imipenem-EDTA doubledisk synergy test, indicating MBL production. The susceptibilities of the isolates to other antimicrobial agents by the disc diffusion method are reported in Table 3 . All of the isolates were found resistant or intermediately resistant to ampicillin, amoxicillin-clavulanate, aztreonam, expanded-spectrum cephalosporins, ciprofloxacin, amikacin, cotrimoxazole, and tetracycline.
The nine K. pneumoniae isolates were PCR positive for the bla VIM gene with both sets of consensus primers. DNA sequencing of the entire bla VIM amplicons showed that all of the isolates carried the novel bla VIM-12 MBL gene. The structure of the bla VIM-12 -containing integron was characterized in three representative K. pneumoniae isolates. The bla VIM-12 gene was inserted as a gene cassette into a class 1 integron. This gene cassette, with its truncated 59-base element, was part of a 5Ј-to-3Ј region and was flanked by two copies of an aacA7 gene cassette which confers resistance to aminoglycosides. A strong P1 promoter and an activated P2 promoter were the promoters of the 5Ј conserved segment sequence. Reverse transcriptase-PCR confirmed that, irrespectively of the carbapenem MICs, the bla VIM-12 gene was expressed in all nine isolates. PCR was negative for the bla IMP , bla SHV-5-type , bla CTX-M , and bla TEM ␤-lactamase genes but positive for bla CMY in all of the isolates.
Conjugation experiments showed that the ceftazidime resistance determinant was successfully transferred to E. coli 26R793 from all nine isolates at transfer frequencies ranging from 1.7 ϫ 10 Ϫ2 to 3.4 ϫ 10 Ϫ5 per recipient cell. Susceptibility testing confirmed the transfer of resistance to ␤-lactams, as well as resistance to amikacin and cotrimoxazole. The molecular sizes of the plasmids transferred from each isolate to E. coli 26R793 were approximately 70 kb. When the plasmid bands of the transconjugants were extracted from the gel and used as templates for the amplification of the bla VIM and bla CMY genes, the specific products were detected, suggesting that both resistance determinants resided in this transferable plasmid. Sequencing of both strands of the entire bla VIM gene amplicons derived from the extracted plasmidic DNA confirmed the presence of bla VIM-12 in the transconjugants. PFGE analysis showed that all of the clinical isolates belonged to a single clone producing the same macrorestriction pattern (Fig. 1) . 
DISCUSSION
This report describes an outbreak caused by a single clone of K. pneumoniae carrying the novel plasmid-mediated bla VIM-12 carbapenem-hydrolyzing ␤-lactamase gene. bla VIM-12 is clustered between bla VIM-1 and bla VIM-2 ; it differs from bla VIM-1 by eight nucleotides that are all located at the 3Ј end and matches exactly the nucleotides found at the corresponding positions in the bla VIM-2 gene (16) . The spread of VIM-12-producing K. pneumoniae in our hospital might be related to the frequent transfer of patients between wards. However, other factors, such as fecal or skin carriage by staff or patients, should not be ignored. Three of the patients had received imipenem and one had received meropenem prior to the isolation of the VIM-12-producing K. pneumoniae strain. Treatment of two of the above patients with imipenem was also continued, given the subsequent laboratory reports (Etest imipenem MIC of 3 g/ ml). The third patient (patient 5) died because of severe injuries soon after the recovery of the imipenem-resistant K. pneumoniae isolate. In most cases, colistin was deemed one of the antimicrobial agents of choice according to the results of the automated system (MICs of Յ0.5 g/liter). It should be mentioned here that we observed some discordant carbapenem susceptibility results between our automated system and the other susceptibility assays. It is of note that similar discordances have been described previously for automated systems, which were also found to overestimate resistance rates (4) . Strict control measures such as isolation of infected patients, hand hygiene, and restriction of carbapenem use as monotherapy were taken, and the outbreak strain was not recovered from other patients in the hospital after the initial outbreak.
K. pneumoniae is recognized as an important pathogen mainly involved in nosocomial infections and outbreaks. The spread of MBL-encoding genes in K. pneumoniae and the emergence of new transferable MBL variants in our region may reflect a heavy usage of carbapenems for the treatment of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa infections, which are common in Greek hospitals. This evolution is worrisome and leaves limited choices for treatment regimens. The accurate and rapid detection of these MBL-producing pathogens is necessary for therapeutic considerations and infection control purposes in order to prevent further dissemination. AMP  AMC  ATM  CAZ  CTX  SXT  FOX  CIP  AMK  FEP  TET   1  R  R  I  R  R  R  R  R  I  I  R  2  R  R  I  R  R  R  R  R  I  I  R  3  R  R  R  R  R  R  R  R  R  I  R  4  R  R  I  R  R  R  R  R  I  I  R  5  R  R  R  R  R  R  R  R  I  I  R  6  R  R  I  R  R  R  R  I  R  I  R  7  R  R  I  R  R  R  R  I  I  R  R  8  R  R  R  R  R  R  R  R  I  I  R  9  R  R  R  R  R  R  R  R  R  I 
